EDG-5506 Reduces Key Biomarkers of Muscle Damage in Early BMD Trial

EDG-5506 Reduces Key Biomarkers of Muscle Damage in Early BMD Trial

315667

EDG-5506 Reduces Key Biomarkers of Muscle Damage in Early BMD Trial

The experimental oral therapy EDG-5506 is generally safe and results in rapid and profound reductions in the levels of muscle damage biomarkers in men with Becker muscular dystrophy (BMD), top-line data from a Phase 1b clinical trial show. “We believe the magnitude of reduction in multiple key biomarkers of muscle damage in adults with BMD after only two weeks of dosing is unprecedented,” Kevin Koch, PhD, president and CEO of Edgewise Therapeutics, which is developing the therapy,…

You must be logged in to read/download the full post.